Slaughter, Katrina N <br/><br/>
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.  [electronic resource] 

 -  Gynecologic oncology  Apr 2014 
 - 11-5 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2014.01.031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adiposity<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Body Mass Index<br/>Carboplatin--administration & dosage<br/>Carcinoma, Ovarian Epithelial<br/>Female<br/>Humans<br/>Intra-Abdominal Fat--diagnostic imaging<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoplasms, Glandular and Epithelial--blood<br/>Obesity--blood<br/>Ovarian Neoplasms--blood<br/>Overweight--blood<br/>Paclitaxel--administration & dosage<br/>Pilot Projects<br/>Prognosis<br/>Proportional Hazards Models<br/>Retrospective Studies<br/>Subcutaneous Fat--diagnostic imaging<br/>Tomography, X-Ray Computed<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--blood